Armata Pharmaceuticals (NYSE: ARMP) names David House Chief Financial Officer

Rhea-AI Filing Summary

Armata Pharmaceuticals, Inc. promoted and appointed David House as Chief Financial Officer, effective July 17, 2026. House had been Senior Vice President, Finance and principal financial officer since August 2024 and will continue to report to the Chief Executive Officer.

Under a new employment letter, House receives an annual base salary of $371,315 and is eligible for a target annual bonus equal to 50% of base salary, with the percentage subject to future increases at the Board’s discretion. The compensation committee currently intends to grant him annual equity awards starting in 2026 with a grant date fair value of about $300,000, on terms consistent with other senior executives. If terminated without Cause or he resigns for Good Reason, he is eligible for 12 months of base-salary continuation, and time-based equity awards fully vest upon an involuntary termination occurring within one month before or 12 months after a Change in Control. The definition of “change in control” in Chief Business Officer Pierre Kyme’s agreement was also conformed to this standard.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

CFO annual base salary: $371,315 Target annual bonus: 50% of base salary Intended annual equity value: $300,000 +4 more

7 metrics

CFO annual base salary $371,315 Annual base salary for David House as Chief Financial Officer

Target annual bonus 50% of base salary Target performance bonus opportunity for David House

Intended annual equity value $300,000 Current intent for grant date fair value of annual equity awards from 2026

Severance duration 12 months Base-salary continuation if terminated without Cause or resigns for Good Reason

Change in Control look-back 1 month prior Equity vesting acceleration window before a Change in Control upon involuntary termination

Change in Control look-forward 12 months following Equity vesting acceleration window after a Change in Control upon involuntary termination

CFO effective date July 17, 2026 Effective date of David House’s appointment as Chief Financial Officer

Key Terms

Change in Control, Good Reason, Cause, grant date fair value, +1 more

5 terms

Change in Control financial

"within one month prior to, or 12 months following, a “Change in Control”"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Good Reason financial

"or if Mr. House resigns for “Good Reason” (as defined in the House Agreement)"

Cause financial

"if the Company terminates Mr. House’s employment without “Cause” (as defined in the House Agreement)"

grant date fair value financial

"with a grant date fair value of approximately $300,000"

The grant date fair value is the estimated dollar worth of a stock-based award (such as stock options or restricted shares) at the exact moment it is given to an employee or contractor. Investors care because companies use that value to record compensation expenses and to show how much potential ownership and earnings dilution those awards could create—think of it as the price tag placed on a gift card when it is handed over so the company can report the cost now.

time-based vesting requirements financial

"equity awards that are subject to time-based vesting requirements will accelerate in full"

Time-based vesting requirements are rules that grant an employee the right to stock, options or other equity only after they work for the company for a set period or reach specific time checkpoints, like earning a reward after paying installments. For investors this matters because it spreads out when new shares can be claimed and sold, affecting future dilution, employee retention, and the timing of potential selling pressure on the stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 07/20/2026 - 07:13 AM Accepted by SEC EDGAR 07/20/2026 - 07:12 AM Learn about SEC filing dates

FAQ

What executive leadership change did Armata Pharmaceuticals (ARMP) announce?

Armata Pharmaceuticals appointed David House as Chief Financial Officer, effective July 17, 2026. He previously served as Senior Vice President, Finance and principal financial officer since August 2024 and will continue reporting to the Chief Executive Officer.

What is the new CFO David House’s compensation at Armata Pharmaceuticals (ARMP)?

David House will receive an annual base salary of $371,315 and is eligible for a target annual bonus equal to 50% of his base salary, with the bonus percentage allowed to increase at the Board’s or compensation committee’s discretion.

What equity awards is Armata Pharmaceuticals (ARMP) planning for its new CFO?

The compensation committee currently intends to grant David House annual equity awards from 2026 with a grant date fair value of about $300,000. He is not guaranteed specific awards, and vesting will follow terms used for other senior executives.

What severance protection does David House have at Armata Pharmaceuticals (ARMP)?

If Armata terminates David House without Cause or he resigns for Good Reason, he is eligible to receive his then-current base salary for 12 months, subject to signing a release and complying with post-employment covenants.

How are David House’s equity awards treated upon a Change in Control of Armata Pharmaceuticals (ARMP)?

If David House experiences an involuntary termination within one month before or 12 months after a Change in Control, all outstanding equity awards subject to time-based vesting will fully vest, subject to the timing described.

What change was made to Pierre Kyme’s agreement at Armata Pharmaceuticals (ARMP)?

Armata Pharmaceuticals updated the “change in control” definition in Chief Business Officer Pierre Kyme’s June 1, 2024 employment letter to match the definition used in David House’s agreement and other senior executive agreements, with all other terms remaining in effect.

false 0000921114 0000921114 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 17, 2026

ARMATA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Washington		001-37544		91-1549568
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

5005 McConnell Avenue, Los Angeles, California		90066
(Address of principal executive offices)		(Zip Code)

(310) 655-2928

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		ARMP		NYSE American

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 17, 2026, the Board of Directors (the “Board”) of Armata Pharmaceuticals, Inc. (the “Company”) promoted and appointed David House as the Company’s Chief Financial Officer, effective July 17, 2026. Mr. House previously served as the Company’s Senior Vice President, Finance and principal financial officer since August 2024. Biographical information regarding Mr. House required by Item 401 of Regulation S-K was previously reported in the Company’s most recent definitive proxy statement filed with the SEC on April 27, 2026.

In connection with Mr. House’s appointment as Chief Financial Officer, the Company and Mr. House entered into an employment letter agreement, dated July 17, 2026 (the “House Agreement”), which confirms the terms of Mr. House’s continued employment with the Company from and after the date thereof. Pursuant to the House Agreement, Mr. House will serve as the Company’s Chief Financial Officer, reporting directly to the Company’s Chief Executive Officer.

Pursuant to the House Agreement, Mr. House will receive an annual base salary of $371,315, and will be eligible for a target annual bonus opportunity equal to 50% of his base salary, with the actual bonus payable based on actual performance as determined by the Board or compensation committee. Mr. House’s annual target performance bonus percentage is subject to increase, but not decrease, from time to time in the discretion of the Board or the compensation committee.

The House Agreement provides that Mr. House will be eligible to receive annual equity awards pursuant to the Company’s 2016 Equity Incentive Plan or any successor plan commencing in 2026. The House Agreement states that the current intent of the compensation committee is to provide Mr. House with an equity award each fiscal year, commencing in 2026, with a grant date fair value of approximately $300,000, but Mr. House is not entitled to any specific award or terms, and any such awards will vest on the same basis as equity awards granted to other senior executives in respect of any fiscal year.

The House Agreement provides that, if the Company terminates Mr. House’s employment without “Cause” (as defined in the House Agreement) other than due to his death or disability, or if Mr. House resigns for “Good Reason” (as defined in the House Agreement), then, subject to his execution of a separation agreement and general release of claims and continued compliance with his post-employment restrictive covenants, Mr. House will continue to receive his then-current base salary for 12 months following such termination. If Mr. House experiences an involuntary termination within one month prior to, or 12 months following, a “Change in Control” (as defined in the House Agreement), the vesting of all of his outstanding equity awards that are subject to time-based vesting requirements will accelerate in full as of the date of such involuntary termination or, if later, the Change in Control.

On July 17, 2026, the Company and Pierre Kyme, the Company’s Chief Business Officer, agreed to conform the definition of “change in control” in Mr. Kyme’s Employment Letter Agreement, dated June 1, 2024 (the “Kyme Agreement”) to the definition in the House Agreement (and other agreements with senior executives of the Company). The Kyme Agreement remains in full force and effect in accordance with its terms with this modified definition.

The foregoing descriptions of the House Agreement and the modification of the Kyme Agreement (the “Kyme Amendment”) do not constitute complete summaries of the terms of the House Agreement or the Kyme Amendment and are qualified in their entirety by reference to the full text of the House Agreement and the Kyme Amendment, which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

- 2 -

Item 9.01. Financial Statements and Exhibits.

(d)       Exhibits

10.1	Employment Letter Agreement, dated July 17, 2026, by and between Armata Pharmaceuticals, Inc. and David House.
10.2	Amendment No. 1, dated July 17, 2026, to that certain Employment Letter Agreement, dated June 1, 2024, by and between Armata Pharmaceuticals, Inc. and Pierre Kyme.
104	Cover Page Interactive Data File (embedded within Inline XBRL document)

- 3 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 18, 2026	Armata Pharmaceuticals, Inc.
	By:	/s/ Deborah L. Birx
	Name:	Deborah L. Birx, M.D.
	Title:	Chief Executive Officer
		(Principal Executive Officer)

- 4 -

Filing Exhibits & Attachments

5 documents

Agreements & Contracts

• EX-10.1 EXHIBIT 10.1 32.7 KB
• EX-10.2 EXHIBIT 10.2 11.5 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.0 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB